We are your partner in drug development

Buy Xanax Pills from Burrard Pharma

What is Xanax Used For?

Xanax is a benzodiazepine and is used to treat anxiety-related disorders. This can include panic attacks, general anxiety disorder, and anxiety associated with depression. Xanax is a short-acting medication which can indicate a need to take it more frequently. As a result, many believe that Xanax is addictive. Xanax is not designed to be a long-term solution for treatment. Doctors prescribe this to act as a sedative so immediate problems can be addressed. They do not recommend taking this drug consistently. The FDA supports this by advising that Xanax and other benzodiazepines should not be taken daily for more than two weeks. The body develops a tolerance to these drugs, which means more are required to achieve the desired effect. You develop a dependence on the drug and this can be a sign of an addiction. The first benzodiazepines were developed in the 1930s but were not used as prescriptions until 1957. By the 1980s, benzodiazepines were the most commonly prescribed drug in the United States. This indicates that they are successful in helping with anxiety, but that they also could be addictive. Addiction or Dependence? There is a clinical difference between addiction and dependence. Taking a drug for a prescribed amount of time changes your brain chemistry. Your brain alters how neurotransmitters are released and this alters the brain’s need for the drug. A physical dependence develops. This drug is now required to achieve the same neurotransmitter function. Dependency is a feature of addiction but not the defining feature. Addiction also involves behavioral aspects such as compulsion. Impaired control, social problems, risky use, and tolerance are also part of addiction. There are many people that become dependent on Xanax in order to feel normal. But is this addiction? Xanax is believed to be addictive for two reasons. It has a rapid onset so the brain immediately flooded with mood-enhancing neurotransmitters. Also, individuals with mental illness are at a greater risk for abusing medications. As Xanax is prescribed for anxiety, the risk of addiction is very high.

How Real is the Addiction?

A decade ago, the majority of emergency room admissions caused by central nervous system depressants were caused by Xanax and other benzodiazepines. Fast forward to a few years ago, and Xanax prescriptions have tripled and fatal overdoses have quadrupled. This trend indicates that the use of Xanax is riskier. Even when prescriptions are decreasing, the rate of overdoses remains high. The age group most commonly associated with Xanax use is between 18 and 29. This group also involves the most use of alcohol, marijuana, MDMA, and other club drugs. The use of Xanax with these other intoxicating drugs is dangerous. Younger adolescents seem to be avoiding substance abuse with the exception of Xanax. Studies report that high school students struggle with Xanax addiction despite being able to abstain from other substances. Many in this group also mix Xanax with opioids which is a dangerous combination.

Does Xanax Lead to Addiction?

Xanax works by binding to receptor cells in the brain to manage the activity of GABA, a neurotransmitter. GABA manages signals between neurons in the brain. The less GABA there is, the slower faster. Xanax allows more GABA to be present which slows neurons and creates calmness. Alcohol is another substance that acts in this way on the brain. Drugs that trigger the brain in this way commonly cause addiction. This explains why alcohol is one of the most abused substances in the world. Xanax binds to receptor cells faster than alcohol, which can make it more addictive. Those struggling with anxiety are looking for peace and this is the sensation they get from Xanax. It can be an addictive feeling. Individuals with anxiety may take it more often so they can feel normal and this can easily develop into drug misuse. When taken specifically to achieve this sensation, the drug is being misused.

Taking Control

Xanax is often mixed with other drugs which makes it more dangerous. It increases the intoxicating effects of other substances. Most commonly, Xanax is mixed with opioids that are taken for pain. This is dangerous and increases the risk of accidental overdose. It is important to discuss other medications with your doctor before taking Xanax. More than 30 percent of opioid overdoses also involve benzodiazepines. Misuse of these drugs is too common and very harmful. If you notice withdrawal symptoms when you are not taking the drug, you are likely struggling with addiction. The only way to end Xanax addiction is through therapy, detox, and rehabilitation.
  • We have over a
    decade of experience
    in pharmaceuticals.

    We have the knowledge and expertise to complete almost any kind of drug formulations.


    Meet our team
    with partners from all over the world

    Dr. Kayhan Moayeri (CEO)

    Read More

    Dr. Kayhan Moayeri is an entrepreneurial pharmacist who specializes in business development and drug discovery with two decades of experience. As CEO of Amerix Pharmaceutical, Dr. Moayeri combines his unique experience in both business and the pharmaceutical industry to oversee the quality operations of the company. Prior to founding Amerix Pharmaceutical, Dr. Moayeri worked at Sanofi, a French multinational pharmaceutical company and a global healthcare leader that is highly focused on patient needs. He then found Amerix Pharmaceutical to head up their global business development division. Dr. Moayeri is an expert in drug formulation, drug discovery, and contract manufacturing. Over the last few years, he has masterminded contract manufacturing projects worth eight figures of Canadian dollars. Dr. Moayeri holds a Doctor of Philosophy in Pharmacy from Azad University and a Master of Business Administration from University of Nebraska-Lincoln.

    Dr. Sandip Kaur Badyal

    Read More

    Dr Sandip Kaur Badyal obtained a PhD in Biological Chemistry from the University of Leicester after which she joined the lab of Professor Bagshaw on a joint venture research project with Dr Kriajevska to study the effects of mobile cells during metastasis. From a relatively short but successful research period, Dr Badyal has 9 publications in peer reviewed journals.

    Dr Badyal decided to move into the field of Regulatory Affairs to pursue her passion to use her scientific knowledge to help others. Whilst mastering the skills of the Regulatory Affairs profession she co-partnered a Regulatory Affairs consultancy in Hamburg, Germany for 3 years. Where she proficiently and successfully worked on the lifecycle management and registering of numerous pharmaceutical products exceeding client expectations.

    Dr Badyal moved to Vancouver, BC, Canada and continues to provide Regulatory Affairs consultancy services whilst also branching out into the field of Medical Devices.

    Dr. Colin Collins

    Read More

    Dr. Collins obtained a PhD in Medical Genetics from the University of British Columbia after which he became faculty at Lawrence Berkeley National Laboratory (LBNL). At LBNL Dr. Collins was a cofounder of the Resource for Molecular Cytogenetics in the Department of Life Sciences. In 1998 Dr. Collins moved to the University of California San Francisco’s (UCSF) Comprehensive Cancer Center. At UCSF Dr. Collins invented and patented “paired end sequencing” and was the first to sequence a tumor genome. He also was the first to show that genome copy number aberrations can be used to risk stratify men with prostate cancer for metastasis. This work also received a patent. In 2009 Dr. Collins relocated to the University of British Columbia (UBC) and the Vancouver Prostate Centre (VPC). At the VPC Dr. Collins Directs the Laboratory for Advanced Genome Analysis (LAGA) and the BGI-VPC Joint Research Laboratory. These support genome and computational biology research within the VPC, Canada and internationally. It also supports a precision oncology program at the VPC. Dr. Collins has a keen interest in treatment resistant prostate cancer where he and his collaborators have made key discoveries into the mechanisms of therapeutic resistance, identification of novel therapeutic targets and the development of liquid biopsies for prostate and other cancers. Dr. Collins has appointments at Simon Fraser University in the School of Computing Science and at BGI in the Think Tank Division. He has over 190 publications and multiple patents.

    Dr. Gary Woodnutt

    Read More

    Recently Dr. Woodnutt has acted as a Consultant to several small Companies in both the Research and Development area to critically evaluate their ongoing projects as well as to provide planning and oversight for Development projects. Dr. Woodnutt served as CSO of Lpath until December 2016 where he led all Discovery and Development activities concerning the exploitation of monoclonal antibodies to bioactive lipids. Prior to that, Dr. Woodnutt served as the Vice President, Open Innovation at Pfizer/CovX from 2012 to 2013, but his primary role at CovX, from 2006 to 2012, was as Vice President of Biology Research. From 2002 to 2006, Dr. Woodnutt was the Senior Vice President of Pharmaceutical Research and Development for Diversa Corporation. He began his career in the pharmaceutical industry with Glaxo SmithKline Pharmaceuticals, where he was employed for more than 20 years and rose to the position of Vice President and Head of Biology in the Antimicrobial and Host Defense Group. Dr. Woodnutt received his Ph.D. in biochemistry/physiology from the University of Reading, and he has authored numerous scientific articles.

    Luca Citton

    Read More

    Luca functions as external legal counsel to Burrard Pharmaceuticals

    Luca Citton is a Shareholder and member of the Board of Directors of Boughton Law. Practicing primarily in the areas of Corporate and Commercial Law, he advises clients on the structuring, sale and continuing operation of a range of businesses, from small and medium enterprises through to national and multinational corporations.

    His extensive client base includes companies in the entertainment, food and beverage, manufacturing, professional services and technology sectors. In addition to corporate and commercial law, Luca maintains an ancillary practice in IP law and is a registered Canadian Trademark Agent.

    Timothy Morris

    Read More

    Mr. Morris brings over 32 years of professional finance and accounting experience and 20 years as a chief financial officer to the Burrard Advisory Board. Mr. Morris has held several CFO roles most recently as chief financial officer and head of business development for AcelRx Pharmaceuticals, a biotechnology company focusing on the development and commercialization of products for the treatment of moderate-to-severe acute pain in medically supervised settings.

    Previous to joining AcelRx, Mr. Morris held the positions of chief financial officer at VIVUS, Inc and Questcor Pharmaceuticals. During his career as CFO, he raised over $980 million in equity and convertible securities for 5 different companies. He has extensive deal experience, having completed over 70 transactions with a combined value in excess of $2.0 billion.

    His work at late-stage biotechnology companies have provided him with valuable experience in regulatory filings and product launches. He has been involved with 4 NDA approvals and applications (including the pending application for DSUVIA, AcelRx’s lead candidate), and 2 MAA approvals (one for ZALVISO, AcelRx’s follow-on candidate, which is approved in Europe). His commercial experience includes the launch of QSYMIA an innovative metabolic small molecule and preparations for the launch of DSUVIA in the US.

    He also serve of the Board of Directors for KaloBios, (KBIO), a biopharmaceutical company focused on rare and orphan disease and on PAION, Inc, the US subsidiary of PAION AG.

    Dr. Patricia-Ann Truter

    Read More

    Dr. Patricia-Ann Truter is a Material Scientist with more than 22 years of product and research and development experience. Her education includes a PhD in Polymer science (Thesis: “The Chemical Development of a Hydrogel to be used as an Artificial Skin”), a MSc in Chemistry (Thesis: “Hydroxy methylation of Kraft Lignin for Novel Adhesive Applications”) and a BSc (Main subjects: Chemistry and Human Physiology). She also attended a 6-week intensive short course: on water soluble polymers at MIT, Boston, USA.

    Patricia is a professional, technical manager with extensive experience in formulation, biomaterial and product development, technology transfer from idea, development, scale up, clinical trials and commercialization (liquids, parenterals, coatings, solid dosage forms. implants, topical products, hydrogels, etc.). She is the inventor and author of > 20 patents, publications, presentations and posters.

    Patricia’s work experience range from Vice President and Chief Scientific Officer: R&D (ARC Medical Devices, Vancouver, BC), Director: R&D (Kisameet, Vancouver, BC), Director: Drug Delivery and Biomaterials (Angiotech Pharmaceuticals, Vancouver, BC,) and a Board member of Ellipsoid Technologies (Pretoria, South Africa). Patricia has worked closely and was involved in technology transfers, clinical batch manufacture with international pharmaceutical companies such as Ethypharm, Abbott Laboratories, SA Druggists and Pfizer.

    Why work with us?




    Get in touch!

    2240 Chippendale Rd West Vancouver,
    BC V7S 3J5

    +1-778-279-3901/ +1-844-9-PHARMA

    Or send us a message